

# Early events in the thymus affect the balance of effector and regulatory T cells

Daniel J. Pennington<sup>1,2</sup>, Bruno Silva-Santos<sup>1,3</sup>, Tobias Silberzahn<sup>1</sup>, Mónica Escórcio-Correia<sup>1</sup>, Martin J. Woodward<sup>4</sup>, Scott J. Roberts<sup>5</sup>, Adrian L. Smith<sup>6</sup>, P. Julian Dyson<sup>7</sup> & Adrian C. Hayday<sup>1</sup>

**In cellular immunology the critical balance between effector and regulatory mechanisms is highlighted by serious immunopathologies attributable to mutations in *Foxp3*, a transcription factor required for a major subset of regulatory T ( $T_R$ ) cells<sup>1–3</sup>. Thus, many studies have focused on the developmental origin of  $T_R$  cells, with the prevailing view that they emerge in the thymus from late-stage T-cell progenitors whose T-cell receptors (TCRs) engage high affinity (agonist) ligands<sup>4–6</sup>. This study questions the completeness of that interpretation. Here we show that without any obvious effect on TCR-mediated selection, the normal differentiation of mouse  $\gamma\delta$  T cells into potent cytolytic and interferon- $\gamma$ -secreting effector cells is switched towards an aggregate regulatory phenotype by limiting the capacity of  $CD4^+CD8^+$  T-cell progenitors to influence *in trans* early  $\gamma\delta$  cell progenitors. Unexpectedly, we found that the propensity of early TCR- $\alpha\beta^+$  progenitors to differentiate into  $Foxp3^+$   $T_R$  cells is also regulated *in trans* by  $CD4^+CD8^+$  T-cell progenitor cells, before agonist selection.**

Thymocyte differentiation progresses from early  $CD4^-CD8^-$  (double negative) progenitors either directly to TCR- $\gamma\delta^+$  cells, or to  $CD4^+CD8^+$  (double positive) cells, which are selected by TCR engagement into mature 'single-positive'  $CD4^+$  and  $CD8^+$  TCR- $\alpha\beta^+$  cells. The double-negative to double-positive transition depends on a pre-TCR comprising TCR- $\beta$  and pre-T $\alpha$  chains, and mice lacking either harbour very few double-positive cells. Of note, double-positive cells function not only as progenitors of single-positive cells, but also 'condition' double-negative cell differentiation *in trans*<sup>7</sup>. Reflecting this,  $\gamma\delta$  cells in pT $\alpha$ -deficient (*Ptcra*<sup>-/-</sup>) and TCR- $\beta$ -deficient (*Tcrb*<sup>-/-</sup>) mice differentiate with abnormally low expression of interferon- $\gamma$  (IFN- $\gamma$ ) and cytolytic effector molecules. Nonetheless, other gene products (for example, XCL1) are expressed normally<sup>7</sup>, suggesting that rather than being generally impaired,  $\gamma\delta$  cell progenitors lacking *trans*-conditioning might differentiate along an alternative pathway. Consistent with this, we found that genes expressed by activated splenic  $\gamma\delta$  cells in *Tcrb*<sup>-/-</sup> but not wild-type mice resembled those expressed by activated skin-resident dendritic epidermal T cells (DETCs) that naturally develop in the fetus before double-positive cells accumulate<sup>8</sup> (Fig. 1a). Resting splenic  $\gamma\delta$  cells showed less resemblance (Fig. 1b), which, together with a lack of DETC-associated V $\gamma$ 5 expression (Supplementary Fig. 1), refutes the possibility that *Tcrb*<sup>-/-</sup> splenocytes are simply DETCs aberrantly localized to the spleen.

On several genetic backgrounds, DETC-deficient mice spontaneously develop cutaneous immunopathologies attributable to dysregulated  $\alpha\beta$  T cells<sup>9</sup>. Thus, although DETCs display cytolytic and pro-inflammatory potentials<sup>10</sup>, their aggregate phenotype *in vivo* is

regulatory. We therefore determined whether activated splenic  $\gamma\delta$  cells in *Tcrb*<sup>-/-</sup> mice also display aggregate regulatory activity. The membranes of TCR- $\alpha\beta^+CD25^{lo}CD4^+$  effector cells were labelled with carboxyfluorescein diacetate succinimidyl ester (CFSE), the dilution of which monitors cytokinesis. At 72 h or 86 h after activation only ~5–10% of cells remained undivided (Fig. 1c). Conversely, in 1:1 and 1:0.1 co-cultures with unlabelled  $CD25^{hi}CD4^+$   $T_R$  cells<sup>11,12</sup>, ~50% and ~20%, respectively, of cells remained undivided. 1:1 co-cultures with wild-type  $\gamma\delta$  splenocytes conferred no such regulation, whereas in co-cultures with  $\gamma\delta$  cells from *Tcrb*<sup>-/-</sup> mice, ~25% of effector T cells remained undivided. This suppressive capacity did not require  $\gamma\delta$  cell subsetting, for example, by CD25 expression. Thus,  $\gamma\delta$  splenocytes developing independently of a normal double-positive pool resemble activated DETCs: both populations contain cytolytic and IFN- $\gamma$ -producing effectors, but on aggregate are regulatory.

Immunoregulation is a critically important function provided by different mechanisms. Whereas natural  $\alpha\beta$   $T_R$  cell activity relies on *Foxp3* transcription<sup>1–3</sup>, other regulatory cells, including DETCs, do not<sup>10</sup>. Indeed, *Foxp3* has not been reported in  $\gamma\delta$  cells, and we could not detect *Foxp3* RNA in TCR- $\gamma\delta^+$  splenocytes from C57.BL/6J or FVB/n mice, or from TCR- $\alpha$ -deficient (*Tcra*<sup>-/-</sup>) mice that lack  $\alpha\beta$  T cells but harbour a large double-positive compartment (Fig. 2a). By contrast, *Foxp3* RNA was amplified from  $\gamma\delta$  cells of *Ptcra*<sup>-/-</sup> and *Tcrb*<sup>-/-</sup> mice, and *Foxp3*-protein-expressing  $\gamma\delta$  cells were reproducibly detected among splenocytes from *Tcrb*<sup>-/-</sup> but not wild-type mice (Fig. 2a, b). Similarly, TCR- $\gamma\delta^+$  double-negative thymocytes from *Tcrb*<sup>-/-</sup> and *Ptcra*<sup>-/-</sup> (but not wild type) mice also expressed *Foxp3* (Fig. 2c, d). Thus, although it was only in a minority (1–2%) of TCR- $\gamma\delta^+$  cells (Supplementary Fig. 2), the expression of *Foxp3* in *Tcrb*<sup>-/-</sup> mice emphasized the switch towards aggregate regulatory T-cell differentiation in the context of double-positive deficiency. Indeed, *Foxp3* RNA was also detected in  $\gamma\delta$  thymocytes from mice lacking lymphotoxin- $\beta$  receptor (LT $\beta$ R) (Fig. 2d) that contributes to *trans*-conditioning by double-positive cells<sup>7</sup>.

Many experiments support the proposal that  $CD4^+CD25^{hi}TCR-\alpha\beta^+$   $T_R$  cells are selected by high-affinity TCR agonist engagement of double-positive cells<sup>4–6</sup>. Thus,  $Foxp3^+$   $\gamma\delta$  cells in *Tcrb*<sup>-/-</sup> mice might reflect an artefactual rescue by TCR- $\gamma\delta$  of double-positive cells that then engage agonist and select as  $T_R$  cells. However, whereas TCR- $\gamma\delta$  will rescue some double-positive differentiation in *Tcrb*<sup>-/-</sup> mice<sup>13</sup>, such TCR- $\gamma\delta^+$  double-positive cells usually die without maturation<sup>13–15</sup>. Indeed, *Foxp3* RNA was not detectable in double-positive cells from *Tcrb*<sup>-/-</sup> mice (Fig. 2e). Moreover, the 'rescue hypothesis' does not obviously explain *Foxp3* RNA in LT $\beta$ R-deficient (*Ltbr*<sup>-/-</sup>)


<sup>1</sup>Peter Gorer Department of Immunobiology, King's College London School of Medicine, Guy's Hospital, London SE1 9RT, UK. <sup>2</sup>Institute of Cell and Molecular Science, The London and Barts School of Medicine and Dentistry, Queen Mary College, London E1 2AT, UK. <sup>3</sup>Instituto de Medicina Molecular, Faculdade de Medicina de Lisboa, Lisboa 1649-028, Portugal. <sup>4</sup>Molecular Haematology and Cancer Biology Unit, Camelia Botnar Laboratories, Institute of Child Health, University College, London WC1N 1EH, UK. <sup>5</sup>Department of Dermatology, 15 York Street HRT 603, Yale University School of Medicine, New Haven, Connecticut 06510, USA. <sup>6</sup>Institute for Animal Health, Compton Laboratory, Compton, Newbury, Berks RG20 7NN, UK. <sup>7</sup>Division of Medicine, Imperial College, Hammersmith Hospital, Du Cane Road, London W12 0HS, UK.

$\gamma\delta$  thymocytes (Fig. 2d). Instead, we pursued the hypothesis that the aggregate regulatory phenotype of  $\gamma\delta$  cells in *Tcrb*<sup>-/-</sup> mice might reflect an uncharacterized route of regulatory T-cell differentiation.


Despite pT $\alpha$  deficiency, some double-negative to double-positive maturation accompanied by limited cell expansion occurs in *Ptcra*<sup>-/-</sup> mice, giving rise to a TCR- $\alpha\beta$ <sup>+</sup>CD4<sup>+</sup> thymocyte pool ~130 times smaller than wild type<sup>16</sup> (Supplementary Table 1). CD25<sup>hi</sup>Foxp3<sup>+</sup> cell numbers are similarly reduced, confirming that the pre-TCR is necessary for T<sub>R</sub>-cell differentiation, but this decline is only ~20-fold, and 25–30% of *Ptcra*<sup>-/-</sup> CD4<sup>+</sup> thymocytes are CD25<sup>hi</sup>Foxp3<sup>+</sup> compared with 2.5–4.5% in wild-type mice (Fig. 3a). Hence, effector and regulatory CD4<sup>+</sup> T cells do not share the same dependence on pT $\alpha$ . CD4<sup>+</sup> cell numbers in the periphery

of *Ptcra*<sup>-/-</sup> mice were less overtly reduced (possibly because of homeostatic expansion), but again effects on T<sub>R</sub> cells were more mild, with the CD25<sup>hi</sup>Foxp3<sup>+</sup> phenotype shown by ~23–32% of CD4<sup>+</sup> splenocytes compared with 6–11% in wild type (Fig. 3b; see also Supplementary Table 1). Moreover, regulatory function per cell was equal to or greater than wild type (Fig. 3c). This enrichment for T<sub>R</sub> cells in *Ptcra*<sup>-/-</sup> mice is highly selective: for example, intestinal TCR- $\alpha\beta$ <sup>+</sup>CD8 $\alpha$ <sup>+</sup> cells are markedly depleted (Supplementary Table 1). Because pT $\alpha$  function precedes double-positive differentiation, its mutation would not be predicted to affect agonist selection into mature CD4<sup>+</sup> (SP4) thymocytes, supporting which the CD4<sup>+</sup> thymocyte TCR repertoire is equivalent to wild type (Supplementary Table 2).

To verify independently the relationship between pT $\alpha$ , double-positive cells and T<sub>R</sub> differentiation, we examined pT $\alpha$  transgenic



**Figure 1 | Activated splenic  $\gamma\delta$  cells from *Tcrb*<sup>-/-</sup> mice express activated DETC-specific genes and display regulatory potential *in vitro*.** **a**, Semi-quantitative RT-PCR on representative ( $n > 3$ ) cDNA from wild-type TCR- $\gamma\delta$ <sup>+</sup> DETCs *ex vivo* (Ex,  $\gamma\delta$  DETC, WT), and anti-CD3 $\epsilon$  monoclonal-antibody-activated wild-type TCR- $\gamma\delta$ <sup>+</sup> DETCs (activated cells,  $\gamma\delta$  DETC, WT), wild-type splenic TCR- $\gamma\delta$ <sup>+</sup> cells (activated cells,  $\gamma\delta$  Spl., WT), and *Tcrb*<sup>-/-</sup> splenic TCR- $\gamma\delta$ <sup>+</sup> cells (activated cells,  $\gamma\delta$  Spl., *Tcrb*<sup>-/-</sup>). **b**, Semi-quantitative RT-PCR for genes as indicated, on representative ( $n > 3$ ) cDNA from resting wild-type splenic TCR- $\gamma\delta$ <sup>+</sup> cells ( $\gamma\delta$  Spl., WT), resting *Tcrb*<sup>-/-</sup> splenic TCR- $\gamma\delta$ <sup>+</sup> cells ( $\gamma\delta$  Spl., *Tcrb*<sup>-/-</sup>) or resting *ex vivo* wild-type TCR- $\gamma\delta$ <sup>+</sup> DETCs ( $\gamma\delta$ , DETC). **c**, CFSE-labelled wild-type CD4<sup>+</sup>CD25<sup>-</sup> splenic T cells ( $5 \times 10^4$ ) were cultured (in triplicate) with either wild-type splenic CD4<sup>+</sup>CD25<sup>-</sup> cells ( $5 \times 10^4$ ), wild-type splenic CD4<sup>+</sup>CD25<sup>+</sup> cells ( $5 \times 10^4$  (Exp. 1);  $5 \times 10^3$  (Exp. 2)), and splenic  $\gamma\delta$  cells ( $5 \times 10^4$ ) from wild-type or *Tcrb*<sup>-/-</sup> mice, plus soluble anti-CD3 $\epsilon$  monoclonal antibody (+antigen presenting cells) for 72 h (Exp. 1) or 86 h (Exp. 2). Average percentage of undivided cells ( $\pm$ s.d.) is indicated.




**Figure 2 |  $\gamma\delta$  cells from *Tcrb*<sup>-/-</sup> and *Ptcra*<sup>-/-</sup> mice express Foxp3.** **a**, Representative ( $n > 3$ ) RT-PCR for *Foxp3* (compared to  $\beta$ -actin) in splenic  $\gamma\delta$  cells from C57Bl/6J or FVB/n strains of wild-type (WT), *Tcrb*<sup>-/-</sup> (A), *Ptcra*<sup>-/-</sup> (P) or *Tcrb*<sup>-/-</sup> (B) mice. The Foxp3<sup>+</sup> control is wild-type splenic TCR- $\alpha\beta$ <sup>+</sup>CD4<sup>+</sup>CD25<sup>+</sup> cells. **b, c**, Representative ( $n > 6$ ) intracellular (i.c.) Foxp3 against TCR- $\gamma\delta$  plots of (Foxp3<sup>+</sup>) splenocytes from wild-type and *Tcrb*<sup>-/-</sup> mice, or thymocytes from wild-type, *Tcrb*<sup>-/-</sup> or *Ptcra*<sup>-/-</sup> mice. As these gatings represent minor populations (see text), representative un-gated plots are shown in Supplementary Fig. 2. Quadrant percentages are indicated. **d, e**, Representative ( $n > 3$ ) RT-PCR for *Foxp3* in thymocytes from wild-type (WT), *Tcrb*<sup>-/-</sup> (B), *Ltbr*<sup>-/-</sup> (LTBR) or *Ptcra*<sup>-/-</sup> (P) mice as in **a**. DN3 is CD4<sup>-</sup>CD8 $\alpha$ <sup>-</sup>TCR- $\alpha\beta$ <sup>-</sup>TCR- $\gamma\delta$ <sup>-</sup>B220<sup>-</sup>NK1.1<sup>-</sup>DX5<sup>-</sup>CD25<sup>+</sup>CD44<sup>-</sup>; DP (double positive) is CD4<sup>+</sup>CD8 $\alpha$ <sup>+</sup>;  $\gamma\delta$  is CD4<sup>-</sup>CD8 $\alpha$ <sup>-</sup>TCR- $\gamma\delta$ <sup>+</sup>.

mice expressing different levels of pT $\alpha$  on wild-type and *Ptcr*<sup>-/-</sup> backgrounds<sup>17</sup>. Such mice confirmed an inverse correlation between double-positive cells and the representation of Foxp3<sup>+</sup> cells among CD4<sup>+</sup> cells: as *Ptcr*<sup>-/-</sup> mice were provided with transgenic pT $\alpha$ , more double-positive cells developed and the regulatory:effector balance declined to normal (2.5–4.5%) (Fig. 3d). This inverse relationship was almost superimposable upon that between double-positive cells and  $\gamma\delta$  cells, expressed as a percentage of total thymocytes<sup>17</sup> (Fig. 3e), but differed completely from the relationship of double-positive cells to unfractionated CD4<sup>+</sup> thymocytes (Fig. 3f).

pT $\alpha$  expression might dictate T<sub>R</sub>-cell representation via a cell-autonomous effect or an effect *in trans*, as exemplified by *trans*-conditioning<sup>7</sup>. To distinguish between these, *Ptcr*<sup>-/-</sup> thymocyte differentiation was examined in sub-lethally irradiated mice reconstituted with admixed *Ptcr*<sup>-/-</sup> and wild-type bone marrow, using congenic markers for each donor and the host. After 10–14 weeks, signatory *Ptcr*<sup>-/-</sup> thymocyte development was evident in a large double-negative compartment, a relatively small double-positive compartment, and some single-positive cells, but this was set against a backdrop of a large double-positive pool supplied by the progeny of wild-type donor and/or recovering host bone marrow (Fig. 4a). In this context, the regulatory:effector ratio among *Ptcr*<sup>-/-</sup> thymocytes was quantified as the percentage of CD4<sup>+</sup> cells displaying the T<sub>R</sub> phenotype. At minimum there was partial rescue, and three of seven mice displayed equivalent regulatory:effector ratios (for example, 3.9% and 4.5%, respectively) in cells derived from *Ptcr*<sup>-/-</sup> and wild-type progenitors. Thus, the establishment of a normal ratio can be rescued *in trans* without any obligatory cell-autonomous

provision of pT $\alpha$ . Because normal double-positive differentiation is associated with increased thymus size, one might consider size as the primary influence on T<sub>R</sub>-cell differentiation. Indeed, a thymus lacking a large double-positive pool does not properly support thymocyte proliferation<sup>18</sup>. However, reflecting variable susceptibility to irradiation, reconstituted thymi varied in size from ~200% to <10% of normal, yet the regulatory:effector cell ratio was similar wherever double-positive cells composed the major thymocyte subset (Fig. 4b). Likewise,  $\gamma\delta$  cells differentiating from *Ptcr*<sup>-/-</sup> progenitors in the context of large double-positive compartments regained the aggregate effector gene profile of wild-type  $\gamma\delta$  cells (data not shown).

Of the four early thymocyte double-negative (DN) stages, *trans*-conditioning targets DN1/DN2 cells (ref. 7 and data not shown) before TCR gene rearrangement. Reflecting this, full genome profiling revealed 360 RNAs  $\geq 2$ -fold upregulated and 97 RNAs reciprocally downregulated in DN2 cells from wild-type compared with *Ptcr*<sup>-/-</sup> mice (data not shown). Upregulated RNAs included the ICER (also known as *Crem*) transcriptional repressor and many other genes (for example, *Nor1*, *Ccl4*, *Rgs1*, *Nurr1* and *Bcl2a1*) that originally identified *trans*-conditioning<sup>7</sup> (Supplementary Table 3). To further characterize *trans*-conditioned cells, we exploited a transgenic mouse in which the ICER promoter drives *lacZ* expression<sup>7</sup>. Numerous *trans*-conditioned genes were expressed more strongly by flow-sorted ICER<sup>hi</sup> DN2 cells, which also appeared as large blasts compared with smaller ICER<sup>lo</sup> cells (Supplementary Fig. 3). This suggested that size could separate conditioned (large) DN2-L thymocytes from unconditioned (small) DN2-S thymocytes using



**Figure 3** | *Ptcr*<sup>-/-</sup> CD4<sup>+</sup>TCR- $\alpha\beta$ <sup>hi</sup> thymocytes and splenocytes are enriched for Foxp3<sup>+</sup> regulatory cells. **a**, **b**, Representative ( $n > 6$ ) CD25 or intracellular (i.c.) Foxp3 plots of wild-type or *Ptcr*<sup>-/-</sup> CD4<sup>+</sup>TCR- $\alpha\beta$ <sup>hi</sup> single-positive thymocytes or splenocytes. Quadrant percentages are indicated. **c**, CFSE-labelled wild-type CD4<sup>+</sup>CD25<sup>-</sup> splenic effector T cells ( $5 \times 10^4$ ) (WT(E)) were cultured (in triplicate) with either wild-type (WT(R)) or *Ptcr*<sup>-/-</sup> (*Ptcr*<sup>-/(R)</sup>) splenic CD4<sup>+</sup>CD25<sup>+</sup> cells in the presence of soluble anti-CD3 $\epsilon$  monoclonal antibody (+ antigen presenting


cells) for 72 h. Average percentage of undivided cells ( $\pm$ s.d.) is indicated. **d–f**, Adult mice thymus ( $n = 18$ ) from *Ptcr*<sup>+/-</sup>.*Lck-Ptcr-transgene*<sup>+/-</sup>  $\times$  *Ptcr*<sup>-/-</sup> crosses were analysed for percentage CD4<sup>+</sup>CD8 $\alpha\beta$ <sup>+</sup> cells (DP cells (%)), percentage TCR- $\gamma\delta$ <sup>+</sup> cells ( $\gamma\delta$  cells (%)) and percentage CD4<sup>+</sup>CD8 $\alpha\beta$ <sup>-</sup> TCR- $\alpha\beta$ <sup>+</sup> single-positive cells (TCR- $\alpha\beta$ <sup>+</sup>CD4<sup>+</sup> SP (%)). The percentage of TCR- $\alpha\beta$ <sup>+</sup>CD4<sup>+</sup> single-positive cells that was also Foxp3<sup>+</sup> was also assessed (Foxp3<sup>+</sup>CD4<sup>+</sup> SP (%)). Lines in the scatter graphs are suggestive of possible correlation.



unmanipulated wild-type mice. Although size-separation is inevitably imprecise (for example, small cells will include conditioned cells that recently underwent cytokinesis), profiling showed that the aggregate transcriptomes of DN2-L and DN2-S cells were distinct, and by hierarchical clustering analysis DN2-S cells resembled *Ptcr*<sup>-/-</sup> DN2 cells more than DN2-L cells (Supplementary Fig. 4), consistent with reduced *trans*-conditioning.

To monitor the developmental potentials of the purified DN2 subsets, paired fetal thymic organ cultures (FTOCs) were used. DN2-S cells differentiated slowly, and by day 8 the double-positive pool was much smaller than in the faster differentiating DN2-L cultures (Fig. 4c). However, SP4 cells arose, and using three independent paired FTOCs harvested on days 13–21, we compared the expression of *Cd25*, *Foxp3* and seven genes (*Gitr*, *Lag3*, *Ppe*, *Ctla4*, *Cd27*, *Cd28* and *Cd122*) reportedly enriched in wild-type CD25<sup>hi</sup> versus CD25<sup>lo</sup> SP4 cells<sup>19–22</sup>. All were overexpressed in CD25<sup>hi</sup> SP4 cells from wild-type and *Ptcr*<sup>-/-</sup> mice, and in SP4 cells derived from DN2-S relative to DN2-L cultures, even without prior CD25 subsetting. Differential expression of *Foxp3* was highly significant at  $P < 0.01$ , as measured by two-tailed *t*-test. Conversely, cyclin D3 was enriched in wild-type CD25<sup>lo</sup> SP4 cells and in DN2-L-derived SP4 cells (Fig. 4d, e). In sum, from wild-type DN2 thymocytes (that temporally precede pre-TCR selection into the double-positive pool and subsequent TCR-mediated selection) one can purify DN2-S cells that show reduced evidence of *trans*-conditioning and that differentiate into

cells enriched in hallmarks of the T<sub>R</sub>-cell phenotype. Unlike other models, these data readily explain the bias towards regulatory differentiation in the  $\alpha\beta$  and  $\gamma\delta$  T-cell compartments of mutant mice lacking normal double-positive compartments. A revised model that may be useful as a basis for further experimentation (Fig. 4f; see also Supplementary Fig. 5) proposes that *trans*-conditioning of DN2 progenitors promotes replication and blasting (DN2-L cells) before further pre-TCR-dependent proliferation at the DN4 to double-positive stage. Their progeny that engage partial agonists positively select as CD4<sup>+</sup> effectors, whereas those engaging agonists on epithelial or bone-marrow-derived cells die by negative selection. Conversely, some DN2 cells will ordinarily receive less *trans*-conditioning, perhaps stochastically, or because of anatomical (niches) and/or cellular heterogeneity. Such cells differentiate as DN2-S cells without overt expansion before pre-TCR-dependent proliferation. The distinct gene expression of DN2-S-derived double-positive cells then dictates that those engaging agonists, for example on epithelial cells, select as T<sub>R</sub> cells, rather than deleting. Thus, whereas effector cell differentiation in *Ptcr*<sup>-/-</sup> mice is impaired by reduced cell-autonomous expansion and *trans*-conditioning, only the former impairs regulatory cell differentiation. Mathematical models are consistent with unconditioned cells being a major source of T<sub>R</sub> cells for which agonist selection<sup>4–6</sup> would be a final, essential manifesting step. It has also been noted that the promotion of T<sub>R</sub>-cell differentiation by SHP-1 deficiency is consistent with T<sub>R</sub> cells arising from a distinct progenitor



**Figure 4 | *Trans*-conditioning regulates the differential capacity of early thymic progenitors to develop into T cells with regulatory characteristics.** **a**, Representative ( $n = 7$ ) CD4/CD8 $\alpha$  plots of wild-type (Ly5.1) and *Ptcr*<sup>-/-</sup> (Ly5.2) donor thymocytes from a 12-week bone-marrow chimaera. **b**, Graph displaying percentage of CD4<sup>+</sup> TCR- $\alpha\beta$ <sup>+</sup> thymocytes that are Foxp3<sup>+</sup> from wild-type and *Ptcr*<sup>-/-</sup> non-chimaeric mice, and from mixed wild-type/*Ptcr*<sup>-/-</sup> bone-marrow chimaeras described in **a**. *P*-values are shown; asterisk,  $P < 0.05$ ; double asterisk, not significant at  $P = 0.05$ . **c**, CD4/CD8 $\alpha$  plots of wild-type DN2 thymocytes (CD4<sup>-</sup> CD8 $\alpha$ <sup>-</sup> TCR- $\alpha\beta$ <sup>-</sup> TCR- $\gamma\delta$ <sup>-</sup> B220<sup>-</sup> NK1.1<sup>-</sup> DX5<sup>-</sup> CD25<sup>+</sup> CD44<sup>+</sup>) size-sorted into the largest 20%, DN2-L, and the smallest 20%, DN2-S, and cultured as 8- or 21-day FTOC ( $1 \times 10^4$  cells per lobe). CD4<sup>+</sup> single-positive (SP) gates for analyses in panels **d** and **e** are shown (ovals). **d**, Representative ( $n = 3$ ) RT-PCR for regulatory T-cell-associated genes in: wild-type CD4<sup>+</sup> CD8 $\alpha$ <sup>-</sup> CD25<sup>-</sup> cells (WT 4<sup>+</sup> 25<sup>-</sup>); wild-type CD4<sup>+</sup> CD8 $\alpha$ <sup>-</sup> CD25<sup>+</sup> cells (WT 4<sup>+</sup> 25<sup>+</sup>); *Ptcr*<sup>-/-</sup> CD4<sup>+</sup> CD8 $\alpha$ <sup>-</sup> CD25<sup>+</sup> cells (*Ptcr*<sup>-/-</sup> 4<sup>+</sup> 25<sup>+</sup>); and CD4<sup>+</sup> CD8 $\alpha$ <sup>-</sup> cells from

13-day FTOC (as described for **c**; DN2-S and DN2-L). **e**, Real-time PCR for Foxp3 in CD4<sup>+</sup> CD8 $\alpha$ <sup>-</sup> cells from 21-day FTOC (as described for **c**). Units for the *y* axis are Foxp3/HPRT ( $\times 10^4$ ). cDNA from *Rag1*<sup>-/-</sup> thymus is a negative control (-ve). Results are significantly different by both two-tailed Student's *t*-test (27.1,  $P < 0.01$ ; SPSS v.13.0 software) and non-parametric Mann-Whitney *U*-test ( $P < 0.05$ ). Data show mean  $\pm$  s.d. **f**, Revised working model for thymic T<sub>R</sub>-cell development. DN2-L cells upregulate gene expression and undergo expansion by *trans*-conditioning (mediated by WT DP cells), whereas DN2-S cells do neither. DN2-L cells develop into conventional double-positive cells that either positively select on partial agonist or negatively select on full agonist. In contrast, DN2-S cells produce a minor, yet distinct double-positive subset that differentiates to CD4<sup>+</sup> T<sub>R</sub> cells when encountering full agonist on epithelial cells. This scheme predicts that pT $\alpha$ -deficiency will reduce total thymocyte output and alter the effector:regulatory T-cell balance towards T<sub>R</sub> cells. Numbers indicate relative thymocyte number (see Supplementary Fig. 5).

pool<sup>23</sup>, which might additionally explain the seeming ceiling on T<sub>R</sub>-cell numbers even in TCR-transgenic mice where there is increased opportunity for agonist selection<sup>24,25</sup>.

That the regulatory:effector balance increases whenever thymic double-positive pools are reduced may partially explain T<sub>R</sub>-cell enhancement in pregnancy, because double-positive cells are depleted, purportedly by steroid hormones<sup>26</sup>. Chronic infections may also deplete thymic double-positive cells, and it will be intriguing if there are parallel increases in regulatory potential, possibly to limit immunopathology. Although lymphotoxin determines several aspects of *trans*-conditioning of  $\gamma\delta$  cells<sup>7</sup>, its contribution to the regulatory:effector balance is less clear. Although its deficiency may reduce conditioning, thus promoting T<sub>R</sub>-cell differentiation, its impairment of AIRE expression may limit T<sub>R</sub>-cell selection. Thus, future studies must aim to define the molecules that act in early thymocyte differentiation to determine the regulatory:effector balance in the  $\alpha\beta$  and  $\gamma\delta$  T-cell compartments.

**Note added in proof:** Since the preparation of this paper, the over-representation of T<sub>R</sub> cells in *Ptcr*<sup>-/-</sup> mice has also been reported, with additional explanations<sup>30</sup>.

## METHODS

**Mice.** Mice have been described previously<sup>16,17,27–29</sup>. For generation of mixed bone-marrow chimaeras,  $5 \times 10^6$  bone-marrow cells from wild-type (C57/Bl6 Ly5.1<sup>+</sup>Thy1.2<sup>+</sup>) or *Ptcr*<sup>-/-</sup> (Ly5.2<sup>+</sup>Thy1.2<sup>+</sup>) mice were mixed at wild-type:*Ptcr*<sup>-/-</sup> ratios of 1:1, 1:5 or 1:10 and injected intravenously into irradiated (900 rad) wild-type recipient mice (C57Bl/6 Ly5.2<sup>+</sup>Thy1.1<sup>+</sup>). Analysis was at 12 weeks.

**Flow cytometry.** Antibodies were from eBioscience or BD Pharmingen. Pre-enriched double-negative thymocytes were obtained by complement lysis (low-tox-M rabbit complement, Cedarlane) of CD4<sup>+</sup> and CD8<sup>+</sup> cells using hybridomas; RL172; 31M (gift of R. Ceredig). Intracellular staining of Foxp3 used the eBioscience protocol (number 72-5775-40). Visualization of  $\beta$ -galactosidase expression has been described<sup>7</sup>.

**RT-PCR.** DNase-treated (RQ1, Promega) total RNA became oligodT-primed cDNA using the PowerScript cDNA synthesis kit (Clontech). Semi-quantitative PCR was performed on cDNA equivalent to  $1-2 \times 10^3$  cells (Advantage2, Clontech) on a Tetrad DNA engine (MJ Research). Real-time PCR was performed on an ABI Prism 7700 Sequence Detection System (PE Applied Biosystems) using SYBR GreenER qPCR SuperMix (Applied Biosystems). For primers see Supplementary Table 4.

**In vitro regulatory T-cell assay.** Sorted, CFSE-labelled (Molecular Probes), wild-type CD4<sup>+</sup>CD25<sup>-</sup> T cells ( $5 \times 10^4$  per well) from lymph node/spleen were targets. Sorted, DDAO-SE-labelled (Molecular Probes), wild-type or *Ptcr*<sup>-/-</sup> lymph node/splenic CD4<sup>+</sup>CD25<sup>+</sup> or  $\gamma\delta$  cells were potential regulators. Red-blood-cell-depleted mitomycin-C-treated (Sigma) splenocytes were used as antigen presenting cells ( $5 \times 10^4$  per well). Cells were mixed in 96-well round-bottom plates, activated with soluble anti-CD3 $\epsilon$  monoclonal antibody (2C-11, Pharmingen) for 72–84 h, and analysed by flow cytometry.

**Fetal thymic organ cultures.** C57Bl/6 day-15 fetal thymic lobes were treated for 5 days with 2-deoxyguanosine (1.35 mM) in FTOC media (RPMI 10% FCS, 50  $\mu$ M  $\beta$ -mercaptoethanol, 10 mM HEPES, L-Glut/Pen/Strep). Hanging-drop cultures in Terasaki plates with  $1 \times 10^4$  thymocytes for 24 h were followed by 8–21-day culture on nucleopore filters in FTOC media, before FACS analysis.

**Transcription profiling.** Total RNA was amplified and labelled by MessageAmp II aRNA amplification kit and Illumina TotalPrep RNA amplification kit (Ambion). cRNA was hybridized to Sentrix Mouse-6 Expression Beadchips (Illumina). Analysis used Genespring GX7.3 (Agilent Technologies).

Received 6 September; accepted 24 October 2006.

Published online 12 November 2006.

- Hori, S., Nomura, T. & Sakaguchi, S. Control of regulatory T cell development by the transcription factor Foxp3. *Science* **299**, 1057–1061 (2003).
- Fontenot, J. D., Gavin, M. A. & Rudensky, A. Y. Foxp3 programs the development and function of CD4<sup>+</sup>CD25<sup>+</sup> regulatory T cells. *Nature Immunol.* **4**, 330–336 (2003).
- Khattry, R., Cox, T., Yasayko, S. A. & Ramsdell, F. An essential role for Scurfin in CD4<sup>+</sup>CD25<sup>+</sup> T regulatory cells. *Nature Immunol.* **4**, 337–342 (2003).
- Jordan, M. S. *et al.* Thymic selection of CD4<sup>+</sup>CD25<sup>+</sup> regulatory T cells induced by an agonist self-peptide. *Nature Immunol.* **2**, 301–306 (2001).
- Apostolou, I., Sarukhan, A., Klein, L. & von Boehmer, H. Origin of regulatory T cells with known specificity for antigen. *Nature Immunol.* **3**, 756–763 (2002).

- Fontenot, J. D. *et al.* Regulatory T cell lineage specification by the forkhead transcription factor foxp3. *Immunity* **22**, 329–341 (2005).
- Silva-Santos, B., Pennington, D. J. & Hayday, A. C. Lymphotoxin-mediated regulation of  $\gamma\delta$  cell differentiation by  $\alpha\beta$  T cell progenitors. *Science* **307**, 925–928 (2005).
- Havran, W. L. & Allison, J. P. Origin of Thy-1<sup>+</sup> dendritic epidermal cells of adult mice from fetal thymic precursors. *Nature* **344**, 68–70 (1990).
- Girardi, M. *et al.* Resident skin-specific  $\gamma\delta$  T cells provide local, nonredundant regulation of cutaneous inflammation. *J. Exp. Med.* **195**, 855–867 (2002).
- Wise, E., Lewis, J., LeClercq, G., Tigelaar, R. E. & Hayday, A. C. Molecular analysis of skin-resident T cells clarifies functional potential, heterogeneity, strain variation and major differences to gut intraepithelial T cells. *J. Immunol.* (submitted).
- Suri-Payer, E., Amar, A. Z., Thornton, A. M. & Shevach, E. M. CD4<sup>+</sup>CD25<sup>+</sup> T cells inhibit both the induction and effector function of autoreactive T cells and represent a unique lineage of immunoregulatory cells. *J. Immunol.* **160**, 1212–1218 (1998).
- Sakaguchi, S., Sakaguchi, N., Asano, M., Itoh, M. & Toda, M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor  $\alpha$ -chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. *J. Immunol.* **155**, 1151–1164 (1995).
- Livak, F., Wilson, A., MacDonald, H. R. & Schatz, D. G.  $\alpha\beta$  lineage-committed thymocytes can be rescued by the  $\gamma\delta$  T cell receptor (TCR) in the absence of TCR $\beta$  chain. *Eur. J. Immunol.* **27**, 2948–2958 (1997).
- Passoni, L. *et al.* Intrathymic  $\delta$  selection events in  $\gamma\delta$  cell development. *Immunity* **7**, 83–95 (1997).
- Buer, J., Aifantis, I., DiSanto, J. P., Fehling, H. J. & von Boehmer, H. Role of different T cell receptors in the development of pre-T cells. *J. Exp. Med.* **185**, 1541–1547 (1997).
- Fehling, H. J., Krotkova, A., Saint-Ruf, C. & von Boehmer, H. Crucial role of the pre-T-cell receptor  $\alpha$  gene in development of  $\alpha\beta$  but not  $\gamma\delta$  T cells. *Nature* **375**, 795–798 (1995).
- Gibbons, D. *et al.* The biological activity of natural and mutant pT $\alpha$  alleles. *J. Exp. Med.* **194**, 695–703 (2001).
- Prockop, S. E. & Petrie, H. T. Regulation of thymus size by competition for stromal niches among early T cell progenitors. *J. Immunol.* **173**, 1604–1611 (2004).
- Fontenot, J. D., Rasmussen, J. P., Gavin, M. A. & Rudensky, A. Y. A function for interleukin 2 in Foxp3-expressing regulatory T cells. *Nature Immunol.* **6**, 1142–1151 (2005).
- Zelenika, D. *et al.* Regulatory T cells overexpress a subset of Th2 gene transcripts. *J. Immunol.* **168**, 1069–1079 (2002).
- Read, S., Malmstrom, V. & Powrie, F. Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25<sup>+</sup>CD4<sup>+</sup> regulatory cells that control intestinal inflammation. *J. Exp. Med.* **192**, 295–302 (2000).
- Takahashi, T. *et al.* Immunologic self-tolerance maintained by CD25<sup>+</sup>CD4<sup>+</sup> regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4. *J. Exp. Med.* **192**, 303–310 (2000).
- Carter, J. D., Calabrese, G. M., Naganuma, M. & Lorenz, U. Deficiency of the Src homology region 2 domain-containing phosphatase 1 (SHP-1) causes enrichment of CD4<sup>+</sup>CD25<sup>+</sup> regulatory T cells. *J. Immunol.* **174**, 6627–6638 (2005).
- van Santen, H. M., Benoist, C. & Mathis, D. Number of T reg cells that differentiate does not increase upon encounter of agonist ligand on thymic epithelial cells. *J. Exp. Med.* **200**, 1221–1230 (2004).
- Lerman, M. A., Larkin, J. III, Cozzo, C., Jordan, M. S. & Caton, A. J. CD4<sup>+</sup>CD25<sup>+</sup> regulatory T cell repertoire formation in response to varying expression of a neo-self-antigen. *J. Immunol.* **173**, 236–244 (2004).
- Aluvihare, V. R., Kallikourdis, M. & Betz, A. G. Regulatory T cells mediate maternal tolerance to the fetus. *Nature Immunol.* **5**, 266–271 (2004).
- Futterer, A., Mink, K., Luz, A., Kosco-Vilbois, M. H. & Pfeffer, K. The lymphotoxin B receptor controls organogenesis and affinity maturation in peripheral lymphoid tissues. *Immunity* **9**, 59–70 (1998).
- Philpott, K. L. *et al.* Lymphoid development in mice congenitally lacking T cell receptor  $\alpha\beta$ -expressing cells. *Science* **256**, 1448–1452 (1992).
- Mombaerts, P. *et al.* Mutations in T-cell antigen receptor genes  $\alpha$  and  $\beta$  block thymocyte development at different stages. *Nature* **360**, 225–231 (1992).
- Bosco, N., Agenes, F., Rolink, A. G. & Ceredig, R. Peripheral T cell lymphopenia and concomitant enrichment in naturally arising regulatory T cells: The case of the pre-T $\alpha$  gene-deleted mouse. *J. Immunol.* **177**, 5014–5023 (2006).

**Supplementary Information** is linked to the online version of the paper at [www.nature.com/nature](http://www.nature.com/nature).

**Acknowledgements** The authors thank the Wellcome Trust for support, and W. Turnbull, E. Wise, G. Warnes, T. Tree, L. Graca, A. Aguirre, P. Pereira, D. Gibbons, S. Haque, Jian-Guo Chai, H. Brady, C. Langford, P. Ellis, J. Lewis, M. Girardi and R. Tigelaar for assistance, support and discussions. T.S. is supported by a Ph.D. scholarship from the Boehringer Ingelheim Fonds.

**Author Information** Reprints and permissions information is available at [www.nature.com/reprints](http://www.nature.com/reprints). The authors declare no competing financial interests. Correspondence and requests for materials should be addressed to D.J.P. ([d.pennington@qmul.ac.uk](mailto:d.pennington@qmul.ac.uk)) or A.C.H. ([adrian.hayday@kcl.ac.uk](mailto:adrian.hayday@kcl.ac.uk)).